PAUL NGUYEN: Open Payments
NPI 1740497346 · N LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,801 in 151 payments from 8 companies in 2025. Trend: 2023 $3,004 · 2024 $2,028 · 2025 $2,801
Food & beverage: $2,801
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 53 | $873 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $488 |
| ABBVIE INC. | 22 | $385 |
| Alkermes, Inc. | 14 | $315 |
| Vanda Pharmaceuticals Inc. | 9 | $225 |
| Supernus Pharmaceuticals, Inc. | 21 | $211 |
| Teva Pharmaceuticals USA, Inc. | 8 | $166 |
| Neurocrine BioSciences, Inc. | 5 | $138 |
Products named: REXULTI, CAPLYTA, VRAYLAR, ARISTADA, FANAPT, Qelbree, ABILIFY ASIMTUFII, UZEDY.
Industry payments across NV — which companies pay providers there.
